NanoViricides, Inc. ASE · NNVC
Price alert —
Sign in to get a one-time email the moment NNVC crosses your price. Free accounts included.
Sign in / create a free accountNanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections.
NNVC last traded at $1.75, down 1.1% on the day; that's in the upper part of its 52-week range ($0.85–$1.93). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.
Earnings reports are the biggest scheduled catalysts to keep an eye on, and after a strong run, watch whether the price can hold its gains on quieter days.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC1 upper, +1.37 ATR from EMA21 — no notable pattern
- · Aligned with weak uptrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · KC1 upper stretch — light pop
- · RSI hook from overbought (63)
- · Stochastic bear cross in overbought
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
On the latest daily bar, momentum sits mid-range (RSI 63), the trend is quiet (ADX 21), and trading is light at 0.5× normal volume.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
The model's verdict is “Unknown” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.
- ✓ More cash than debt
- ✓ Debt/equity 0.17 (antifragile)
- ⚠ Negative retained earnings
NNVC is a $40 million company, it moves harder than the market (beta 1.7).
Options idea
See more →About
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient …